Targeting Fear of Cancer Recurrence in Cancer Survivors: Evaluation of Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as Intervention Strategies
Launched by GENERAL HOSPITAL GROENINGE · Dec 8, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Despite our adequate medical care and financial support systems, the mental wellbeing and quality of life after cancer diagnosis and treatment is often poorly addressed in clinical settings. Previous research showed that Fear of Cancer Recurrence (FCR) is one of the most common psychological burdens faced by 39%-97% of cancer survivors. In this phase III randomized multicentre trial, patients will be allocated to either the iEFT group, iMMI group or wait-list control (WLC) group for a study trajectory of 6 weeks. 339 cancer survivors, between 6 months and 5 years since diagnosis, and who ha...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients should have reached a minimum age of 18 years at the time of enrolment
- • Patients should have a histologically confirmed diagnosis of a solid cancer or haematologic malignancy
- • Patients should have completed surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy or a combination of these at least 2 months ago and no longer than 5 years ago at the time of enrolment
- • Patients should have an expected life expectancy of at least 5 years
- • Patients are disease-free at the time of enrolment, as defined by the absence of somatic disease activity parameters
- • Patients can be included in a stable phase of their immunotherapy (e.g. adjuvant use of checkpoint inhibitors for melanoma), hormonal therapy (e.g. for breast and prostate cancer), targeted drug therapy (e.g. trastuzumab and pertuzumab for breast cancer; stable dose of PARP inhibitors for ovarian cancer; retuximab for lymphoma), or a combination of these
- • Patients must suffer from high FCR based on the Cancer Worry Scale (cut-off ≥ 14)
- • Patients should be able to adequately communicate in Dutch
- • Patients should present with a sufficient mental and physical functional status (according to investigator's judgment and first baseline assessment) for completing the questionnaires and neuropsychological assessment
- • Patients under current treatment for a depression or anxiety disorder are allowed to enrol provided their depression or anxiety disorder is stable
- Exclusion Criteria:
- • Patients who received a treatment with palliative intent
- • Patients showing signs of mental deterioration
- • Patients suffering from organic brain syndrome (concussion without neurological symptoms and negative imaging is allowed)
- • Patients who are alcohol or drug dependent
- • Patients with another serious or chronic medical, neurologic or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in either of the intervention programmes or from the measurement of intervention outcomes; a prior diagnosis of a depressive, anxiety or adjustment disorder is allowed
- • Patients who cannot commit to the intervention schedule; obstacles such as surgery or long-term hospitalisation, change of residence or work, ... can have an emotional and practical impact which makes these patients not eligible for participation.
- • Patients who actively practice EFT or mindfulness(based) meditation
About General Hospital Groeninge
General Hospital Groeninge is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust infrastructure for conducting research, the hospital collaborates with multidisciplinary teams to explore new therapies and treatment protocols across various medical fields. By prioritizing patient safety and ethical standards, General Hospital Groeninge plays a pivotal role in the development of evidence-based medicine, contributing to the global medical community's understanding of health challenges and therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bonheiden, , Belgium
Edegem, Antwerp, Belgium
Leuven, Vlaams Brabant, Belgium
Tongeren, , Belgium
Ronse, , Belgium
Hasselt, , Belgium
Jette, , Belgium
Brasschaat, Antwerp, Belgium
Sint Niklaas, , Belgium
Gent, East Flanders, Belgium
Kortrijk, West Flanders, Belgium
Antwerp, , Belgium
Patients applied
Trial Officials
Philip R Debruyne, MD, PhD
Principal Investigator
Kortrijk Cancer Centre,General Hospital Groeninge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported